Cybin Reports Q2 GAAP EPS of -$1.41, Missing Estimates by $0.68
Cybin has reported second-quarter financial results featuring a GAAP earnings per share (EPS) of -$1.41, which represents a significant miss compared to analyst expectations by $0.68. The company's liquidity position remains tight, reporting working capital of $177,060 as of September 30, 2026. The earnings miss comes amid ongoing clinical development efforts for its serotonergic agonist pipeline aimed at treating mental health conditions. While the financial results are weak, market attention remains focused on the company's ability to fund upcoming clinical milestones and navigate the regulatory landscape for psychedelic-based therapeutics.
Tickers: $HELP
Topics: earnings_report psychedelics quarterly_results working_capital